Imaging of tumour response to immunotherapy.

Détails

Ressource 1Télécharger: 31900689_BIB_152AC98411BD.pdf (8716.00 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_152AC98411BD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Imaging of tumour response to immunotherapy.
Périodique
European radiology experimental
Auteur⸱e⸱s
Dromain C., Beigelman C., Pozzessere C., Duran R., Digklia A.
ISSN
2509-9280 (Electronic)
ISSN-L
2509-9280
Statut éditorial
Publié
Date de publication
03/01/2020
Peer-reviewed
Oui
Volume
4
Numéro
1
Pages
2
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
A wide range of cancer immunotherapy approaches has been developed including non-specific immune-stimulants such as cytokines, cancer vaccines, immune checkpoint inhibitors (ICIs), and adoptive T cell therapy. Among them, ICIs are the most commonly used and intensively studied. Since 2011, these drugs have received marketing authorisation for melanoma, lung, bladder, renal, and head and neck cancers, with remarkable and long-lasting treatment response in some patients. The novel mechanism of action of ICIs, with immune and T cell activation, leads to unusual patterns of response on imaging, with the advent of so-called pseudoprogression being more pronounced and frequently observed when compared to other anticancer therapies. Pseudoprogression, described in about 2-10% of patients treated with ICIs, corresponds to an increase of tumour burden and/or the appearance of new lesions due to infiltration by activated T cells before the disease responds to therapy. To overcome the limitation of response evaluation criteria in solid tumors (RECIST) to assess these specific changes, new imaging criteria-so-called immune-related response criteria and then immune-related RECIST (irRECIST)-were proposed. The major modification involved the inclusion of the measurements of new target lesions into disease assessments and the need for a 4-week re-assessment to confirm or not confirm progression. The RECIST working group introduced the new concept of "unconfirmed progression", into the irRECIST. This paper reviews current immunotherapeutic approaches and summarises radiologic criteria to evaluate new patterns of response to immunotherapy. Furthermore, imaging features of immunotherapy-related adverse events and available predictive biomarkers of response are presented.
Mots-clé
Cell- and tissue-based therapy, Immune checkpoint inhibitors, Immunotherapy, Pseudoprogression, Response evaluation criteria in solid tumors (RECIST)
Pubmed
Open Access
Oui
Création de la notice
10/01/2020 16:56
Dernière modification de la notice
15/01/2021 8:08
Données d'usage